Skip to main content
. Author manuscript; available in PMC: 2015 May 5.
Published in final edited form as: Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162

Fig. 4. Intrapleurally administered M28z T cells eradicate pleural tumor and establish long-term CD4+ predominant persistence.

Fig. 4

(A) CD28 costimulation facilitates tumor eradication following a single dose of T cells. In total, 1×105 CAR+ Mz, M28z, or P28z (negative control) T cells were intrapleurally administered into mice bearing established tumors. (Left) Tumor burden. (Right) Kaplan-Meier survival curve. Median survival of the Mz and M28z groups (at least 9 mice per group) was 63 days and median survival not reached, respectively. Survival curve was analyzed by log-rank test. **P<0.01. (B) CD28 costimulation enhances CAR+ T-cell persistence. Absolute CAR+ T-cell counts (per mL of peripheral blood) at 50 days after intrapleural administration of 3×106 CAR+ T cells. Error bars represent ±SEM, *P < 0.05 by Student's t test. (C) Persisting CAR+ T cells are predominantly CD4+. (Left) FACS analysis of peripheral blood in treated mice. (Right) CD4:CD8 ratios determined at successive time points following T-cell administration. The preinfusion CD4:CD8 ratio was approximately 0.5. Results shown are similar across a range of T-cell doses (3×106, 1×106, and 3×105 CAR+, n=3 mice at each time point). *P<0.05 by Student's test with Bonferroni correction for multiple comparisons comparing ratio at each time point to the preinfusion CD4:CD8 ratio. Raw data and P values are provided in the Supplementary Materials.